NCT03091192 2026-04-14
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
Phase 3 Active not recruiting
AstraZeneca
H. Lee Moffitt Cancer Center and Research Institute
University Hospital, Toulouse
VA Office of Research and Development
Chinese University of Hong Kong
University of Colorado, Denver
Brigham and Women's Hospital